Head and Neck Cancers

Latest News

Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC
Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC

March 6th 2024

Although frontline treatment with lenvatinib plus pembrolizumab improved ORR and PFS, it did not improve OS when compared with placebo in patients with head and neck squamous cell carcinoma.

Opinion: ctHPVDNA Testing Could Improve Surveillance in Oropharyngeal Squamous Cell Carcinoma
Opinion: ctHPVDNA Testing Could Improve Surveillance in Oropharyngeal Squamous Cell Carcinoma

January 18th 2024

head and neck cancer
Treatment Decision-Making in Head and Neck Cancer

December 13th 2023

head and neck cancer
Methylene Blue Has Potential to Transform Mucositis Management in Head and Neck Cancer

November 23rd 2023

Despite Treatment Advances, Oral Mucositis Continues to Plague Patients With Head and Neck Cancer
Despite Treatment Advances, Oral Mucositis Continues to Plague Patients With Head and Neck Cancer

November 21st 2023

Video Interviews
Podcasts
Latest CME Events & Activities

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.